Literature DB >> 29317098

A case of paraneoplastic neuromyelitis optica associated with small cell lung carcinoma.

Lisa M Deuel1, Marjorie E Bunch2.   

Abstract

Neuromyelitis optic spectrum disorders are demyelinating conditions that are typically idiopathic, though various case reports have demonstrated an association with malignancy. We present the case of a 64year old woman with NMOSD in the setting of small cell lung cancer. She had longitudinally extensive transverse myelitis and left eye optic neuritis; aquaporin-4 antibodies were elevated. Biopsy of mediastinal adenopathy was positive for SCLC. Malignancy should be considered in any patient with an atypical presentation of NMOSD, or who does not respond to traditional therapies.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Neuromyelitis optica spectrum disorders; Optic neuritis; Paraneoplastic conditions; Small cell lung cancer

Mesh:

Year:  2018        PMID: 29317098     DOI: 10.1016/j.jneuroim.2018.01.003

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  3 in total

1.  Paraneoplastic neuromyelitis optica spectrum disorders: a case series.

Authors:  Eleonora Virgilio; Domizia Vecchio; Marco Vercellino; Paola Naldi; Fabiana Tesser; Roberto Cantello; Paola Cavalla; Cristoforo Comi
Journal:  Neurol Sci       Date:  2021-01-28       Impact factor: 3.307

2.  Aquaporin-4-Positive Triple-Negative Breast Cancer Presenting with Paraneoplastic Neuromyelitis Optica Spectrum Disorder.

Authors:  Pilar Carrillo; Teresa Gorría; Daniel Santana; Maria Sepulveda; Iban Aldecoa; Blanca Gonzalez-Farré; Esther Sanfeliu; Eduard Mension; Isaac Cebrecos; Olga Martínez-Saez; Imma Alonso; Albert Saiz
Journal:  Biomed Hub       Date:  2022-01-31

3.  Paraneoplastic neuromyelitis optica spectrum disorder associated with malignant melanoma: A case report.

Authors:  Toshiki Morimoto; Shotaro Hayashida; Kei Yamasaki; Yosuke Sasahara; Tsutomu Takaki; Kazuhiro Yatera
Journal:  Thorac Cancer       Date:  2021-05-05       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.